RCGE - ETF AI Analysis

Top Page

RockCreek Global Equality ETF (RCGE)

Rating:58Neutral

Price Target:―

The RockCreek Global Equality ETF (RCGE) has a balanced overall rating, reflecting a mix of strong and moderate-performing holdings. Key contributors include Johnson & Johnson and Merck, which benefit from robust financial performance, strategic investments, and positive earnings outlooks. However, weaker holdings like ACEA SPA and Iberdrola, with challenges such as declining revenue and high debt levels, may have slightly held back the fund's rating. A notable risk is the ETF's exposure to companies with overbought technical signals, which could lead to short-term volatility.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid returns so far this year, indicating strong overall performance.

Global Diversification

The fund invests in companies across multiple countries, reducing reliance on any single geographic region.

Exposure to Stable Sectors

The ETF includes significant allocations to traditionally stable sectors like Financials and Health Care.

Negative Factors

High Expense Ratio

The ETF charges a relatively high fee, which could eat into investor returns over time.

Underperforming Holdings

Some top holdings, such as Charles River Labs and Land Securities Group, have shown weaker year-to-date performance.

Limited Emerging Market Exposure

The fund has minimal exposure to emerging markets, potentially missing out on higher-growth opportunities.

RCGE Historical Chart

AUM86.36M

RegionGlobal

Expense Ratio0.95%

Beta0.68

IssuerRockCreek

Inception DateFeb 26, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,268

30 Day Avg. Volume6,842

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

31.32

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering192

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

RCGE Summary

The RockCreek Global Equality ETF (RCGE) is an actively managed fund that invests in large companies worldwide, focusing on those committed to gender equality in their corporate structures. It includes well-known firms like Johnson & Johnson and Exelon, offering exposure to industries such as healthcare, financials, and technology. This ETF is ideal for investors who want to align their investments with social values while aiming for growth and diversification. However, new investors should note that the fund’s performance can fluctuate with the broader market, and its focus on gender-balanced companies may limit exposure to other potentially high-performing firms.

How much will it cost me?The RockCreek Global Equality ETF (RCGE) has an expense ratio of 0.95%, which means you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because it’s an actively managed fund, requiring more research and oversight compared to passively managed ETFs that track an index.

What would affect this ETF?The RockCreek Global Equality ETF (RCGE) could benefit from growing global interest in socially responsible investing and corporate diversity, as well as potential economic growth in both developed and emerging markets. However, it may face challenges from rising interest rates, which could impact sectors like real estate and financials, or economic slowdowns that affect large-cap companies globally. Additionally, its focus on gender equality may limit its investment universe, potentially reducing diversification compared to broader ETFs.

RCGE Top 10 Holdings

The RockCreek Global Equality ETF is leaning heavily on healthcare and utilities, with names like Johnson & Johnson and Endesa SA providing steady support thanks to their strong financial performance and bullish momentum. AstraZeneca is also rising, driven by robust revenue growth and strategic progress, while Merck’s mixed results and slight year-to-date decline are holding back some gains. The fund’s global exposure adds diversity, but its focus on large-cap companies ensures stability. Overall, the ETF is well-positioned, though some holdings face challenges that could temper its upward trajectory.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
BIIB	Biogen	0.63%	$544.67K	$26.60B	14.91%	74 Outperform
GM	General Motors	0.63%	$541.18K	$70.94B	42.39%	73 Outperform
MRK	Merck & Company	0.62%	$531.49K	$247.51B	-3.27%	81 Outperform
4503	Astellas Pharma	0.61%	$526.74K	¥3.60T	20.24%	73 Outperform
VFC	VF	0.61%	$526.22K	$7.44B	-9.50%	59 Neutral
BAYN	Bayer	0.59%	$512.26K	€32.72B	68.60%	51 Neutral
NWG	NatWest Group	0.59%	$510.33K	£49.40B	49.21%	75 Outperform
VRTX	Vertex Pharmaceuticals	0.59%	$509.96K	$115.56B	-1.43%	78 Outperform
IG	Italgas S.p.A.	0.59%	$509.69K	€9.43B	78.95%	67 Neutral
GSK	GlaxoSmithKline	0.59%	$508.17K	£72.87B	34.30%	77 Outperform

RCGE Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

27.80

Positive

100DMA

27.65

Positive

200DMA

Market Momentum

MACD

0.11

Negative

RSI

57.84

Neutral

STOCH

97.00

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RCGE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 27.78, equal to the 50-day MA of 27.80, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 57.84 is Neutral, neither overbought nor oversold. The STOCH value of 97.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RCGE.

RCGE Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
RCGE	―	―	$86.36M	0.95%	―
BLCR	―	―	$47.97M	0.36%	―
GPT	―	―	$22.32M	0.69%	―
NBGX	―	―	$12.73M	0.44%	―
FFLV	―	―	$12.07M	0.38%	―
JDIV	―	―	$9.46M	0.47%	―

Performance Comparison

RCGE

RockCreek Global Equality ETF

28.15

3.55

14.43%

BLCR

BlackRock Large Cap Core ETF

―

GPT

Intelligent Alpha Atlas ETF

―

NBGX

Neuberger Berman Growth ETF

―

FFLV

Fidelity Fundamental Large Cap Value ETF

―

JDIV

JPMorgan Dividend Leaders ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents